Lupin introduces Honeywell Solstice Air inhalers for sustainable respiratory care
Lupin is now utilizing Honeywell’s Solstice Air in its respiratory inhalers, significantly improving respiratory care with propellants that have near-zero global warming potential. This advancement, designed for asthma and COPD patients, reduces greenhouse gas emissions by up to 99.9% compared to traditional HFC-based propellants, marking a substantial stride in decreasing carbon emissions.
Lupin is now utilizing Honeywell’s Solstice Air in its respiratory inhalers, significantly improving respiratory care with propellants that have near-zero global warming potential. This advancement, designed for asthma and COPD patients, reduces greenhouse gas emissions by up to 99.9% compared to traditional HFC-based propellants, marking a substantial stride in decreasing carbon emissions.
